Loading...
XKRX
033780
Market cap13bUSD
Oct 08, Last price  
177,400.00KRW
1D
-1.22%
1Q
2.25%
Jan 2017
75.64%
Name

KT&G Corp

Chart & performance

D1W1MN
XKRX:033780 chart
P/E
16.83
P/S
2.80
EPS
10,542.14
Div yield, %
3.83%
Shrs. gr., 5y
-1.04%
Rev. gr., 5y
4.41%
Revenues
6.58t
+11.35%
3,046,384,220,0003,363,531,491,0003,626,353,016,0003,461,418,375,0003,722,965,820,1003,911,818,274,7203,782,629,860,3904,101,425,018,3004,134,035,080,2304,468,855,746,1604,667,193,482,2504,471,515,592,0604,963,202,297,0005,301,617,654,0005,228,351,597,0005,851,406,368,0005,862,608,000,0005,908,792,000,0006,579,595,000,000
Net income
1.09t
-6.12%
662,605,613,000892,396,038,000851,090,632,0001,031,823,366,000805,592,737,890721,107,661,300564,678,435,340809,277,195,2801,047,220,980,5501,210,186,965,2201,210,988,575,960906,350,260,1201,035,003,181,0001,171,734,473,000977,258,705,0001,015,785,000,000902,662,000,0001,165,727,000,0001,094,384,000,000
CFO
628.42b
-23.58%
904,100,837,000716,819,438,000831,112,908,150845,111,227,960756,854,135,880765,575,839,720594,616,223,300760,920,772,9201,258,912,454,0601,488,813,403,5701,141,485,070,800822,057,209,0001,042,489,387,0001,261,664,798,0001,419,821,289,000887,886,607,0001,265,993,000,000822,275,000,000628,415,000,000
Dividend
Aug 20, 20262000 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

KT&G Corporation, a diversified South Korean enterprise that operates alongside its subsidiaries, specializes in a broad array of industries. Its primary business involves the manufacturing and distribution of tobacco products and related materials. Beyond this, the company is a significant provider of health and wellness items, offering red ginseng, various red ginseng-based goods, and other health-focused foods. Its extensive product portfolio also features food and beverage items, along with cosmetic and beauty products. Further diversifying its operations, KT&G offers support services for leaf tobacco cultivation and maintains a presence in the pharmaceutical and medical sectors. This includes the development, production, and supply of pharmaceuticals, encompassing bio-pharmaceuticals, over-the-counter medicines, and a range of medical supplies and equipment. The corporation also holds investments in commercial ventures such as trading, real estate management, property leasing, and housing development. Additionally, it is involved in the development and ongoing management of hotels. Founded in 1987, the company originally operated under the name Korea Tobacco and Ginseng Corporation before officially changing to KT&G Corporation in December 2002. Its corporate headquarters are situated in Daejeon, South Korea.

Key people

Gwan Su Son
Chairman, Non-Executive Independent Director · since 2024
Hak Yeong Doh
Vice President · since 2022
Chi Beom Oh
Vice President · since 2022
Seong Mun Cho
Managing Director · since 2023
Jae Yeong Cho
Managing Director · since 2021
Min Seok Gwon
Managing Director · since 2024
Seong Heon Jung
Managing Director · since 2022
Tae Seong Kim
Managing Director · since 2024
Yong Beom Kim
Managing Director · since 2024
Jeong Ho Kim
Managing Director · since 2023
Seung Jun Lee
Managing Director · since 2024
Jeong Jin Lee
Managing Director · since 2021
Seong Sik Park
Managing Director · since 2023
Dong Ok Song
Managing Director · since 2023
Jun Han Yim
Managing Director · since 2024
Seung Gyu Baek
Assistant Managing Director · since 2024
Hyeong Cheol Cha
Assistant Managing Director · since 2019
Jae Yeong Choi
Assistant Managing Director · since 2021
Yong Hwan Han
Assistant Managing Director · since 2019
Dong Won Han
Assistant Managing Director · since 2019
IPO date
Oct 08, 1999
Employees
Domiciled in
KR
Incorporated in
KR
Headquarters & legal address
대전광역시 대덕구 벚꽃길 71 (평촌동, KT&G)
KT&G
Daejeon Metropolitan City, 30 34337
KR
Address
71, Beotkkot-gil, Daedeok-gu, Daejeon
KT&G
Daejeon Metropolitan City, 30 34337
KR
Other language
KT&G Corporation

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT